AI
By
At VivaTech 2025, Can NVIDIA, Sanofi, and TetraScience Unlock the Full Potential of Scientific AI Despite a 20-Exabyte Data Barrier?
Key Highlights The 20-Exabyte Problem: Data, Not Models, Is the Limiting FactorAt The Rise of Scientific AI panel…
Is AstraZeneca’s $20M AI Hub in Bengaluru the Catalyst for 20 New Medicines by 2030?
Key Highlights Strategic Investment to Scale AI-Driven InnovationAstraZeneca has inaugurated a state-of-the-art Global Hub in Bengaluru with an…
Will Samsung’s Acquisition of Xealth Spark a New Era of AI-Driven Mobile Healthcare in the U.S.?
Key Highlights Samsung Expands into AI Healthcare with Xealth DealSamsung Electronics has announced its acquisition of Xealth, a…
Can Lisata Therapeutics and GATC Health’s AI Breakthrough Redefine Drug Discovery and Tackle the Opioid Crisis in Just One Year?
Key Highlights AI-Powered Drug Discovery Moves Toward the Clinic with OUD FocusLisata Therapeutics and GATC Health have expanded…
Could Chai’s $70 Million OpenAI-Backed Funding Propel the Next Leap in AI-Engineered Drug Discovery Success?
Key Highlights Breakthrough Funding and Industry BackingThe Series A round brings Chai Discovery’s total capital to $100 million,…
Is Illinois’ Ban on AI in Mental Healthcare a Turning Point for Human-Centered Therapy Regulation in the U.S.?
Key Highlights Background and Impetus for the BanDriven by incidents where AI chatbots posed risks—including cases suggesting harmful…
